Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Single Agent, Phase I/II Trial Investigating the Safety and Efficacy of RVU120 (SEL120) in Patients with Relapse / Refractory Metastatic or Advanced Solid Tumors

Next Previous
Trial Profile

An Open-label, Single Agent, Phase I/II Trial Investigating the Safety and Efficacy of RVU120 (SEL120) in Patients with Relapse / Refractory Metastatic or Advanced Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RVU 120 (Primary)
  • Indications Adenoid cystic carcinoma; Advanced breast cancer; Colorectal cancer; Gastric cancer; Male breast cancer; Malignant thymoma; Oesophageal cancer; Pancreatic cancer; Solid tumours; Testicular cancer; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AMNYS-51
  • Sponsors Ryvu Therapeutics

Most Recent Events

  • 07 Nov 2024 According to a Ryvu Therapeutics media release, the company were present data from this study at the 2024 EORTC-NCI-AACR (ENA) Symposium (October 23-25, Barcelona, Spain).
  • 28 Oct 2024 Status changed from recruiting to active, no longer recruiting.
  • 25 Oct 2024 Results assessing the safety and tolerability of RVU120, a CDK8/19 inhibitor, in patients with solid tumors published at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top